NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 10 May 2022

**Location:** via Zoom

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice-chair) Present for all items
3. Professor Abdallah Al-Mohammad Items 1 to 6.1.3
4. Dr Peter Baker-Gulliver Items 4.1.3 to 6.2.2
5. Richard Ballerand Present for all items
6. Dr Andrew Champion Present for all items
7. Ana Duarte Present for all items
8. Dr Steve Edwards Present for all items
9. Professor Khalida Ismail Items 1 to 6.1.3
10. Professor G.J. Melendez-Torres Items 1 to 6.1.3
11. Hugo Pedder Items 4.1.3 to 6.2.2
12. Dominic Pivonka Present for all items
13. Dr Mohit Sharma Items 4.1.3 to 6.2.2
14. Alan Thomas Present for all items
15. Min Ven Teo Items 1 to 5.2.2
16. Dr Roger Whittaker Present for all items

NICE staff present

Janet Robertson, Associate Director Items 1 to 4.2.2

Henry Edwards, Associate Director Items 5 to 6.2.2

Thomas Feist, Project Manager Items 1 to 4.2.2

Jeremy Powell, Project Manager Items 5 to 6.2.2

Mary Hughes, Heath Technology Assessment Adviser Items 1 to 4.2.2

Rufaro Kausi, Heath Technology Assessment Adviser Items 5 to 5.2.2

Michelle Green, Heath Technology Assessment Adviser Items 6 to 6.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 1 to 4.2.2

Albany Meikle, Heath Technology Assessment Analyst Items 1 to 4.2.2

Anne Murray-Cota, Heath Technology Assessment Analyst Items 1 to 4.2.2

Sana Khan, Heath Technology Assessment Analyst Items 5 to 5.2.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 6 to 6.2.2

Raphael Egbu, Heath Technology Assessment Analyst Items 6 to 6.2.2

Adam Storrow, Business Analyst, RIA Items 1 to 5.2.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment Items 1 to 4.2.2

Stephen Norton, Technical Analyst, Managed Access Items 1 to 4.2.2

Catrin Austin, Technical Analyst, Methods, and Economics Items 5 to 5.2.2

Neha Jiandani, Technical Analyst, Commercial Liaison Items 6 to 6.2.2

Olivia Havercroft, Senior Medical Editor Items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Items 6 to 6.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3

Lyn Davies, Coordinator, MIP Items 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Marcia Miller, Administrator, TA Items 1 to 4.2.2

Rumana Zaman, Administrator, TA Items 5 to 5.2.2

Laura Kelly, Administrator, COT Items 6 to 6.2.2

External assessment group representatives present

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Bram Ramaekers, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Luke Vale, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Diarmuid Coughlan, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Katy Cooper, School of Health, and Related Research (ScHARR) Items 6 to 6.1.3

Paul Tappenden, School of Health, and Related Research (ScHARR) Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, present for all items

Jo Gumbs, Patient expert nominated by OcuMelUK, items 1 to 4.1.3

Rumana Hussain, Consultant Ocular Oncologist, Clinical expert nominated by Royal College of Pathologists, items 1 to 4.1.3

Dr Paul Nathan, Consultant Medical Oncologist, Clinical expert nominated by Melanoma Focus and Immunocore, items 1 to 4.1.3

Holly Heath, Patient expert nominated by Breast Cancer Now, items 5 to 5.1.3 & 6 to 6.1.3

Dr Olga Oikonomidou, Senior Clinical Lecturer in Breast Cancer Medicine and Honorary Consultant Medical Oncologist, Clinical expert nominated by Eli Lilly, items 5 to 5.1.3

Dr Andreas Makris, Consultant Clinical Oncologist, clinical expert nominated by Eli Lilly, items 5 to 5.1.3

Dr Catherine Harper-Wynne, Consultant Medical Oncologist, Clinical expert nominated by NCRI-ACP-RCP-RCR, items 6 to 6.1.3

NICE Observer present

Peter Groves, Non-executive Director, NICE, recently appointed appeal panel member, items 1 to 5.2.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 12 April 2022

### Appraisal of tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]

* 1. Part 2a – Closed session The Medicines and Healthcare Products Regulatory Agency (MHRA) has not yet made its decision on the marketing authorisation for this technology, therefore this discussion was held in a private part 2 session only, without the public in attendance.
     1. The chair welcomed the invited experts, external assessment group representatives and company representatives from Immunocore.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Dr Paul Nathan declared direct financial interests as he has received payment for advisory board membership and speaker’s bureau for multiple pharmaceutical companies including Immunocore. It was agreed his declaration would not prevent Dr Nathan from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Roger Whittaker, Dr Brian Shine, and Alan Thomas.
  1. Part 2b – Closed session (company representatives, clinical and patient experts, and external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10428> .

### Appraisal of albemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive HER2-negative node-positive early breast cancer [ID3857]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated patient expert Holly Heath declared indirect financial interests as in the last 12 months Breast Cancer Now has received funding from the manufacturer Eli Lilly and possible comparator companies Novartis and Pfizer either towards their living with secondary breast cancer support service or service pledge work with hospitals. It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
* Nominated clinical expert Dr Andreas Makris declared direct financial interests as he has received advisory board and speaker fees from Eli Lilly. It was agreed that his declaration would not prevent Dr Makris from providing expert advice to the committee.
* Nominated clinical expert Dr Olga Oikonomidou declared direct non-financial interests as she is the local PI on the MonarchE and the MONARCHER study. It was agreed that her declaration would not prevent Dr Oikonomidou from providing expert advice to the committee.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Jane Adam and Dr Mohit Sharma.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10749>

### Appraisal of Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative PIK3CA-mutated breast cancer [ID3929]

* 1. Part 1 – Open session
     1. The chair Dr Brian Shine welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated patient expert Holly Heath declared indirect financial interests as in the last 12 months Breast Cancer Now has received funding from the manufacturer Novartis and possible comparator companies Lilly UK and Pfizer either towards our living with secondary breast cancer support service or our service pledge work with hospitals. It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
* Nominated clinical expert Dr Catherine Harper-Wynne declared financial interests as she has acted as an advisor on advisory boards for Novartis for other agents and received honoraria as chair of an educational meeting conducted by Novartis for this agent. It was agreed her declarations would not prevent Dr Harper-Wynne from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10825>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 7 June 2022 and will start promptly at 09.30.